SLC5A2 and type 2 diabetes mellitus: In a recent meta-analysis conducted by Hu et al. [39] on randomized controlled trials involving patients with type 2 diabetes mellitus (T2DM) in Asia, it was observed that SGLT-2 inhibitors, including Empagliflozin, significantly lowered serum uric acid (SUA) levels compared to the control group [MD = − 0.965, 95% CI (− 1.029, − 0.901)].